|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM362216517 |
| 003 |
DE-627 |
| 005 |
20240209231928.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202306081
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1285.xml
|
| 035 |
|
|
|a (DE-627)NLM362216517
|
| 035 |
|
|
|a (NLM)37724825
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Deng, Bo
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Oral Nanomedicine
|b Challenges and Opportunities
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.02.2024
|
| 500 |
|
|
|a Date Revised 09.02.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Compared to injection administration, oral administration is free of discomfort, wound infection, and complications and has a higher compliance rate for patients with diverse diseases. However, oral administration reduces the bioavailability of medicines, especially biologics (e.g., peptides, proteins, and antibodies), due to harsh gastrointestinal biological barriers. In this context, the development and prosperity of nanotechnology have helped improve the bioactivity and oral availability of oral medicines. On this basis, first, the biological barriers to oral administration are discussed, and then oral nanomedicine based on organic and inorganic nanomaterials and their biomedical applications in diverse diseases are reviewed. Finally, the challenges and potential opportunities in the future development of oral nanomedicine, which may provide a vital reference for the eventual clinical transformation and standardized production of oral nanomedicine, are put forward
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a bioavailability
|
| 650 |
|
4 |
|a biomedical applications
|
| 650 |
|
4 |
|a nanomaterials
|
| 650 |
|
4 |
|a nanomedicine
|
| 650 |
|
4 |
|a oral administration
|
| 650 |
|
7 |
|a Pharmaceutical Preparations
|2 NLM
|
| 700 |
1 |
|
|a Liu, Shaomin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Ying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ali, Barkat
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kong, Na
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xie, Tian
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koo, Seyoung
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ouyang, Jiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tao, Wei
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 6 vom: 18. Feb., Seite e2306081
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:6
|g day:18
|g month:02
|g pages:e2306081
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202306081
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 6
|b 18
|c 02
|h e2306081
|